Skip to content

Dr. Silke Van Genechten

Active
Private limited companyfounded 2023active for 3 yearsMeistraat 12, 3600 Genk, BelgiumKBO/BCE: BE 0797.194.597
Summary

The annual accounts of Dr. Silke Van Genechten for financial year 2025 show a net loss of 84% of the equity at the start of that year. The 2025 annual accounts show equity of €4,314 and a net result of -€22,990. Equity has been shrinking by about 47% per year since 2023. If that trend continues, it turns negative around financial year 2026. Its solvency ranks better than 10% of 20,720 sector peers (NACE 86, financial year 2025). The company has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.2% (very low).

Overview

Official details

Source: KBO
Status
Active since 16-01-2023 Normal situation
Activity
Specialist medical practice NACE 86220
Establishment unit
2.341.056.990 3600 Genk, since 16-01-2023
Financial year end
31 December
Peppol
Reachable

Board and ownership

Board
Shareholders
  • VAN GENECHTEN Silkeact of 18-01-2023

Financial position

52 Fair Checked score 2025
Bankruptcy probabilitywithin 12 months
0.2%
Annual accounts 2025
Gross margin
-€6,450
Loss
€22,990
▲ 810%
Equity
€4,314
▼ 84.2%
Total assets
€87,581
▲ 61.1%
Turnover not published (micro format)
Score breakdownraises riskCapped at 59: a net loss of at least half of total assets or of the equity at the start of the financial yearEquity €4,314 (4.9% of total assets)lowers riskSector: Human health activities (NACE 86)Size: total assets €87,581Figures for financial year 2025 (filed on 27-07-2026)Show the evidence

Checked score

Score 2025
52 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially stronger than 6% of micro companies in human health (NACE 86)
A net loss of at least half of total assets or of the equity at the start of the financial year caps the score at 59. Every signal that counts is listed under Signals.
Financial strength · tick: 2024
Weak
Solvency 30-45
equity 4.9% of total assets
Liquidity 26-37
short-term debt 79.8% · cash 15.4%
Profitability 0-63
return on assets -26.2%
Bankruptcy probability within 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%

About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,173 companies, NACE 86, micro)
Last 24 months 12-2024: < 0.1%lowest value 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: 0.1%▲ +0.1 percentage points vs 01-2025 03-2025: 0.1%● unchanged vs 02-2025 04-2025: 0.1%● unchanged vs 03-2025 05-2025: 0.1%● unchanged vs 04-2025 06-2025: 0.1%● unchanged vs 05-2025 07-2025: 0.1%● unchanged vs 06-2025 08-2025: 0.2%▲ +0.1 percentage points vs 07-2025 09-2025: 0.1%▼ -0.1 percentage points vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025 02-2026: 0.1%● unchanged vs 01-2026 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026 07-2026: 0.2%▲ +0.1 percentage points vs 06-2026 08-2026: 0.2%● unchanged vs 07-2026highest value 09-2026: 0.2%● unchanged vs 08-2026 10-2026: 0.2%● unchanged vs 09-2026 11-2026: 0.2%● unchanged vs 10-2026
No publishable credit limit, so credit only on tighter terms
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity is insufficient, with a current ratio of 0.24 (0.91 in 2024), below 1. Short-term debt is 79.8% and cash 15.4% of total assets. 95.1% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 10% of them on solvency, 4% on liquidity, 1% on profitability and 6% on growth.

The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

The probability rests on the annual accounts with balance sheet date 31-12-2025.

Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Seven signals.
lowers riskraises riskneutral
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Size: total assets €87,581
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
raises risk · Equity €4,314 (4.9% of total assets)
NBB · annual accounts
lowers risk · Figures for financial year 2025 (filed on 27-07-2026)
NBB · annual accounts
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025
Net result per financial year
232425
2023 to 2025 · latest year -€22,990
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 10% of 20720 sector peers (2025).
NBB · sector comparison
Position among 20720 sector peers
Solvency
better than 10%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-07-2026, 4 days ahead of the deadline.
NBB · 3 filings
Deviation from the deadline
2025
4 days early
2024
29 days late
2023
31 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 3 accounts on average 19 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 August (3 of the last 3 accounts filed within 33 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
05-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since incorporation in 2023.
KBO publications

Key points

  • Caution: Lower net result than 95% of companies in human healthsector median €60,150 · 20,707 companies -€22,990 View
  • Caution: 2 loss-making years in a rowloss in financial year 2025 -€22,990 View

Recent changes

  1. · Gazette deed Company renamed from Dr. Silke Van Genechten - Cardiothoracaal Chirurg to Dr. Silke Van Genechten“De uitoefening van de geneeskunde volgens de betreffende wetgeving door de arts-aandeelhouder, meer in het…” (deed in Dutch)
  2. · Gazette deed IncorporationFounding capital of €3,500, 100 shares · Founder: VAN GENECHTEN Silke · Appointment: VAN GENECHTEN Silke (director)
All 6 events

Comparable companies

These companies have the same main activity as Dr. Silke Van Genechten: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €67,400 and €105,000, founded between 2021 and 2023.

CompanyTotal assetsGross margin
Dr. Silke Van Genechten Genk€87,581-€6,450
DOKTER JASPER TRUYENS Knokke-Heist€104,104-€16,083
Dr. Katrien Ernes – Psychiater Hasselt€95,209-€23,307
E. de Witte Holding Lanaken€84,603€992
YAA Medics Antwerpen€94,040-€25,578
G FLAMEE Ichtegem€105,411-€19,483
Terryn Surgical Sint-Pieters-Woluwe€67,362-€20,586
Full comparison

Key facts about Dr. Silke Van Genechten

What is the company number of Dr. Silke Van Genechten?
The company number of Dr. Silke Van Genechten is 0797.194.597. The VAT number is the same number with BE in front: BE 0797.194.597.
Where is Dr. Silke Van Genechten based?
The registered office is at Meistraat 12, 3600 Genk.Company details
What does Dr. Silke Van Genechten do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of Dr. Silke Van Genechten?
The legal form of Dr. Silke Van Genechten is Private limited company (BV).
When was Dr. Silke Van Genechten founded?
Dr. Silke Van Genechten was founded on 16-01-2023.
Is Dr. Silke Van Genechten still active?
Yes, Dr. Silke Van Genechten is an active enterprise in the KBO register.
What is the turnover of Dr. Silke Van Genechten?
The annual accounts for financial year 2025 state no turnover. The micro format does not require it.Financials
Is Dr. Silke Van Genechten profitable?
In financial year 2025, Dr. Silke Van Genechten made a loss of €22,990.
Where can I find the annual accounts of Dr. Silke Van Genechten?
Dr. Silke Van Genechten filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Dr. Silke Van Genechten due?
Dr. Silke Van Genechten must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.